Oncology Central

The challenge of managing adrenocortical carcinoma: two case studies

0

Adrenocortical carcinoma is a rare entity affecting 1–2 people per million. It has a relatively poor prognosis, with an overall 5-year survival of 20–45%. The reasons include a high risk of recurrence following resection and relatively poor response to cytotoxic treatment. The use of the adrenalytic mitotane as adjuvant therapy is supported by level III evidence from cohort studies.

To view restricted content, please:
Share:

Leave A Comment